Analyst firms · Morgan Stanley · EMR
Morgan Stanley EMR price target and rating history
Emerson Electric Company (EMR) · Technology
Morgan Stanley rates Emerson Electric Company (EMR) Underweight with a $105 price target, as of its latest action on Sep 6, 2024. It has published 5 rating actions on EMR since August 2021, including 1 upgrade and 0 downgrades. Across 8 firms with a EMR price target in the last 12 months, the median target is $169.
- Current rating
- Underweight
- Price target
- $105
- Median target, all firms
- $169
- Actions on EMR
- 5
Morgan Stanley price target on EMR
Every Morgan Stanley rating on EMR
- Sep 6, 2024
- Mar 21, 2023
- Feb 3, 2022
- Oct 7, 2021
- Aug 5, 2021
How other firms rate EMR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| DA Davidson | Neutral | $145 | Jun 16, 2026 |
| Bernstein | Outperform | $175 | Jun 10, 2026 |
| Jefferies | Buy | $175 | Mar 31, 2026 |
| BMO Capital Markets | Market Perform | $150 | Mar 27, 2026 |
| Deutsche Bank | Hold | $170 | Feb 5, 2026 |
| Oppenheimer | Perform | Jan 27, 2026 | |
| TD Cowen | Hold | $150 | Jan 9, 2026 |
| UBS | Buy | $168 | Jan 5, 2026 |
| Evercore ISI | Outperform | $170 | Dec 15, 2025 |
Questions about Morgan Stanley and EMR
- What is Morgan Stanley's price target for EMR?
- Morgan Stanley's latest stated price target for Emerson Electric Company (EMR) is $105, from its action on Sep 6, 2024.
- What is Morgan Stanley's rating on EMR?
- Morgan Stanley rates EMR Underweight, a bearish rating, as of Sep 6, 2024.
- When did Morgan Stanley last change its view on EMR?
- On Sep 6, 2024, Morgan Stanley starts coverage at Underweight, price target $105.
- How does Morgan Stanley's EMR target compare with other analysts?
- Across 8 firms with a EMR price target in the last 12 months, the median target is $169.
More EMR rating histories
All Morgan Stanley ratingsEMR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.